peptuity.
WhatsApp

home / compounds / Tirzepatide

FDA approvedMetabolic & fat loss

Tirzepatide

Mounjaro, Zepbound

Dual GIP/GLP-1 agonist. Approved, and outperformed semaglutide in head-to-head trials.

01

What it is

A dual agonist acting on both GIP and GLP-1 receptors, approved as Mounjaro and Zepbound.

02

What it does

Combines incretin pathways to reduce appetite and improve insulin sensitivity, with weight-loss magnitudes above single-agonist GLP-1 drugs.

Does it work?

Backed by large phase 3 programmes and regulatory approval. As with semaglutide, this is prescription medicine, not a research compound, and belongs under physician supervision.

03

Claims vs data

Each marketing claim, tagged by what the evidence actually supports.

Greater average weight loss than semaglutidesupported
Requires no medical supervisionoverreach
04

Reference figures

Quoted from published reference material. These are not Peptuity recommendations.

Vial10 mg
Diluent2 ml
Listed dose0.5 mg
Units / 1 ml10

Open in the calculator — prefilled →

05

The evidence, counted

Live counts from Europe PMC and ClinicalTrials.gov.

Publications 6,419
Randomised trials 182
Clinical trials 158
Registered studies 239

6,419 publications indexed, including 182 randomised controlled trials. 239 interventional studies registered. This is a well-tested compound.

query: "Tirzepatide" · checked 2026-08-07

Most-cited literature

Regulatory status

Formal, dated regulatory actions.

WADA — Prohibited List 2026

Not on the WADA Prohibited List

source →

06

Common questions

How does tirzepatide compare with semaglutide?

In head-to-head trial data tirzepatide produced greater average weight loss. Individual response and tolerability still vary, which is a clinical conversation.

Is it approved in Saudi Arabia?

Yes, as a prescription medicine under its brand names. Anything sold outside that channel is unregulated product.

Why do the incretin drugs dominate the news feed?

Because they are in active large-scale clinical development. Most compounds on this site generate almost no new registered trials; these generate hundreds.

07

Related compounds

FDA approved

Semaglutide

GLP-1 agonist. Approved, trial-backed, and genuinely effective for weight and glycaemic control.
Well researched

Retatrutide

Triple agonist with the strongest phase 2 weight results yet — but not approved anywhere.
Emerging

Cagrilintide

Amylin analogue, mainly studied combined with semaglutide.

Research use only

All content on Peptuity is provided for research and educational purposes only. Peptuity does not sell, distribute, or facilitate the purchase of any compound, does not provide medical advice, and makes no claims regarding safety or efficacy. Most compounds discussed are not approved for human use by the SFDA or FDA. Always consult a qualified physician.

Ask a question